S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
How this AP photographer captured a unique splash at the swimming worlds with an underwater camera
Critical asset just had biggest fall on record (Ad)
Tax-free status of movie, music and games traded online is on table as WTO nations meet in Abu Dhabi
Delays in promised Western military aid to Ukraine are costing lives, the defense minister says
Laser breakthrough could send stock soaring 2,467% (Ad)
MILAN FASHION PHOTOS: Feben, Rave Review promote looks for women of all shapes, ages and sizes
Caribbean leaders meet with Haiti's prime minister. Foreign force deployment is on the agenda
Laser breakthrough could send stock soaring 2,467% (Ad)
Stock market today: Asian shares mostly decline, while Tokyo again touches a record high
The Eiffel Tower reopens to visitors after a 6-day closure due to an employee strike
S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
How this AP photographer captured a unique splash at the swimming worlds with an underwater camera
Critical asset just had biggest fall on record (Ad)
Tax-free status of movie, music and games traded online is on table as WTO nations meet in Abu Dhabi
Delays in promised Western military aid to Ukraine are costing lives, the defense minister says
Laser breakthrough could send stock soaring 2,467% (Ad)
MILAN FASHION PHOTOS: Feben, Rave Review promote looks for women of all shapes, ages and sizes
Caribbean leaders meet with Haiti's prime minister. Foreign force deployment is on the agenda
Laser breakthrough could send stock soaring 2,467% (Ad)
Stock market today: Asian shares mostly decline, while Tokyo again touches a record high
The Eiffel Tower reopens to visitors after a 6-day closure due to an employee strike
S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
How this AP photographer captured a unique splash at the swimming worlds with an underwater camera
Critical asset just had biggest fall on record (Ad)
Tax-free status of movie, music and games traded online is on table as WTO nations meet in Abu Dhabi
Delays in promised Western military aid to Ukraine are costing lives, the defense minister says
Laser breakthrough could send stock soaring 2,467% (Ad)
MILAN FASHION PHOTOS: Feben, Rave Review promote looks for women of all shapes, ages and sizes
Caribbean leaders meet with Haiti's prime minister. Foreign force deployment is on the agenda
Laser breakthrough could send stock soaring 2,467% (Ad)
Stock market today: Asian shares mostly decline, while Tokyo again touches a record high
The Eiffel Tower reopens to visitors after a 6-day closure due to an employee strike
S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
How this AP photographer captured a unique splash at the swimming worlds with an underwater camera
Critical asset just had biggest fall on record (Ad)
Tax-free status of movie, music and games traded online is on table as WTO nations meet in Abu Dhabi
Delays in promised Western military aid to Ukraine are costing lives, the defense minister says
Laser breakthrough could send stock soaring 2,467% (Ad)
MILAN FASHION PHOTOS: Feben, Rave Review promote looks for women of all shapes, ages and sizes
Caribbean leaders meet with Haiti's prime minister. Foreign force deployment is on the agenda
Laser breakthrough could send stock soaring 2,467% (Ad)
Stock market today: Asian shares mostly decline, while Tokyo again touches a record high
The Eiffel Tower reopens to visitors after a 6-day closure due to an employee strike
NASDAQ:MDWD

MediWound (MDWD) Stock Price, News & Analysis

$13.40
+0.14 (+1.06%)
(As of 02/23/2024 ET)
Today's Range
$13.32
$13.45
50-Day Range
$10.17
$13.49
52-Week Range
$7.10
$14.01
Volume
17,421 shs
Average Volume
31,215 shs
Market Capitalization
$123.36 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$32.00

MediWound MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
138.8% Upside
$32.00 Price Target
Short Interest
Healthy
0.93% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($0.81) to ($1.56) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.32 out of 5 stars

Medical Sector

741st out of 936 stocks

Medicinals & Botanicals Industry

8th out of 11 stocks


MDWD stock logo

About MediWound Stock (NASDAQ:MDWD)

MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in United States, Europe, and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. The company also develops EscharEx, which has completed Phase II clinical trials for the debridement of chronic and other hard-to-heal wounds; MW005, which is in phase I/II for the treatment of low-risk basal cell carcinoma. MediWound Ltd. was incorporated in 2000 and is headquartered in Yavne, Israel.

MDWD Stock Price History

MDWD Stock News Headlines

MediWound (NASDAQ:MDWD) Upgraded to "Hold" at StockNews.com
Laser breakthrough could send stock soaring 2,467%
Laser breakthrough could send stock soaring 2,476% Whenever the military develops a breakthrough technology, timely investors could see groundbreaking returns. General Dynamics returned 8,990%... Boeing soared 4,238%... L3Harris shot up 1,628%...
MediWound Shares Climb on Positive Data for EscharEx
Laser breakthrough could send stock soaring 2,467%
Laser breakthrough could send stock soaring 2,476% Whenever the military develops a breakthrough technology, timely investors could see groundbreaking returns. General Dynamics returned 8,990%... Boeing soared 4,238%... L3Harris shot up 1,628%...
Recap: MediWound Q3 Earnings
MediWound Q3 2023 Earnings Preview
MediWound to Report Third Quarter 2023 Financial Results
See More Headlines
Receive MDWD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for MediWound and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/21/2023
Today
2/25/2024
Next Earnings (Estimated)
3/21/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Medicinals & botanicals
Sub-Industry
N/A
Current Symbol
NASDAQ:MDWD
Employees
83
Year Founded
2001

Price Target and Rating

Average Stock Price Target
$32.00
High Stock Price Target
$36.00
Low Stock Price Target
$28.00
Potential Upside/Downside
+138.8%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Net Income
$-19,600,000.00
Pretax Margin
-49.27%

Debt

Sales & Book Value

Annual Sales
$24.97 million
Book Value
$1.51 per share

Miscellaneous

Free Float
8,359,000
Market Cap
$123.36 million
Optionable
Optionable
Beta
0.91

Social Links

10 Best Stocks to Own in 2024 Cover

Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio.

Get This Free Report

Key Executives

  • Mr. Ofer Gonen B.Sc. (Age 51)
    Chief Executive Officer
    Comp: $485k
  • Dr. Lior Rosenberg M.D. (Age 78)
    Co-Founder
    Comp: $727k
  • Dr. Ety Klinger MBA (Age 62)
    Ph.D., Chief Research & Development Officer
    Comp: $393k
  • Ms. Hani Luxenburg
    Chief Financial Officer
  • Dr. Shmulik Hess Ph.D.
    COO & Chief Commercial Officer
  • Mr. Yaron Meyer Adv. (Age 45)
    Executive VP, General Counsel & Corporate Secretary
    Comp: $240k
  • Mr. Barry J. Wolfenson (Age 57)
    Executive Vice President of Strategy & Corporate Development
  • Dr. Robert J. Snyder CWS (Age 74)
    D.P.M., F.A.C.F.A.S., FFPM, M.B.A., M.Sc., Chief Medical Officer














MDWD Stock Analysis - Frequently Asked Questions

Should I buy or sell MediWound stock right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for MediWound in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" MDWD shares.
View MDWD analyst ratings
or view top-rated stocks.

What is MediWound's stock price target for 2024?

2 Wall Street research analysts have issued twelve-month price targets for MediWound's stock. Their MDWD share price targets range from $28.00 to $36.00. On average, they expect the company's stock price to reach $32.00 in the next year. This suggests a possible upside of 138.8% from the stock's current price.
View analysts price targets for MDWD
or view top-rated stocks among Wall Street analysts.

How have MDWD shares performed in 2024?

MediWound's stock was trading at $10.17 at the beginning of 2024. Since then, MDWD stock has increased by 31.8% and is now trading at $13.40.
View the best growth stocks for 2024 here
.

Are investors shorting MediWound?

MediWound saw a increase in short interest in January. As of January 31st, there was short interest totaling 57,600 shares, an increase of 6.3% from the January 15th total of 54,200 shares. Based on an average daily volume of 28,300 shares, the short-interest ratio is presently 2.0 days. Approximately 0.9% of the company's shares are sold short.
View MediWound's Short Interest
.

When is MediWound's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, March 21st 2024.
View our MDWD earnings forecast
.

How were MediWound's earnings last quarter?

MediWound Ltd. (NASDAQ:MDWD) announced its earnings results on Tuesday, November, 21st. The biopharmaceutical company reported ($0.24) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.45) by $0.21. The biopharmaceutical company had revenue of $4.78 million for the quarter, compared to analyst estimates of $4.73 million. MediWound had a negative trailing twelve-month return on equity of 44.32% and a negative net margin of 49.79%. During the same quarter in the previous year, the firm posted ($0.91) earnings per share.

When did MediWound's stock split?

MediWound's stock reverse split before market open on Tuesday, December 20th 2022. The 1-7 reverse split was announced on Tuesday, December 20th 2022. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, December 20th 2022. An investor that had 100 shares of stock prior to the reverse split would have 14 shares after the split.

What other stocks do shareholders of MediWound own?

Based on aggregate information from My MarketBeat watchlists, some companies that other MediWound investors own include OPKO Health (OPK), Sorrento Therapeutics (SRNE), Blackstone (BX), Dynavax Technologies (DVAX), Geron (GERN), Idera Pharmaceuticals (IDRA), Mastercard (MA), SCYNEXIS (SCYX), Vascular Biogenics (VBLT) and Wells Fargo & Company (WFC).

Who are MediWound's major shareholders?

MediWound's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Yelin Lapidot Holdings Management Ltd. (1.36%), Sargent Investment Group LLC (1.19%), Silverberg Bernstein Capital Management LLC (0.86%), Sphera Funds Management LTD. (0.53%), Essex Investment Management Co. LLC (0.42%) and Citadel Advisors LLC (0.18%).

How do I buy shares of MediWound?

Shares of MDWD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:MDWD) was last updated on 2/25/2024 by MarketBeat.com Staff